Technical Analysis for HTBX - Heat Biologics, Inc.

Grade Last Price % Change Price Change
grade D 0.6087 4.59% 0.03
HTBX closed up 4.59 percent on Thursday, September 19, 2019, on 24 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical HTBX trend table...

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
MACD Bullish Centerline Cross Bullish 0.00%
180 Bullish Setup Bullish Swing Setup 0.00%
NR7 Range Contraction 0.00%
Upper Bollinger Band Walk Strength 0.00%
Weak + Overbought Other 0.00%
Weak, Overbought and Reversal Signs Reversal 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%

Older signals for HTBX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Heat Biologics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of various cellular therapeutic vaccines for a range of cancers and infectious diseases. It is developing Immune Pan Antigen Cytotoxic therapy, a platform technology that delivers human cells that are reprogrammed to pump out various cancer associated antigens together with a potent immune adjuvant. The company's products under development include HS-110 that is in Phase II clinical trials for the treatment of non-small cell lung cancer; HS-410 for the bladder cancer treatment; HS-310 to treat ovarian cancer; and HS-510 for treating triple negative breast cancer. Its products also comprise HS-HIV product candidate for the treatment and prevention of HIV. The company was founded in 2008 and is based in Chapel Hill, North Carolina.
Biotechnology Biopharmaceutical Cancer Life Sciences Infectious Diseases Treatment Of Cancer Cancers Non Small Cell Lung Cancer Ovarian Cancer Vaccination Cancer Treatment HIV Platform Technology Vaccine Cancer Vaccine Treatment Of Non Small Cell Lung Cancer Biotechnology Companies Bladder Cancer Triple Negative Breast Cancer Chapel Hill Heat Biologics Neuvenge
Is HTBX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 2.24
52 Week Low 0.46
Average Volume 219,694
200-Day Moving Average 0.9822
50-Day Moving Average 0.5824
20-Day Moving Average 0.5457
10-Day Moving Average 0.5649
Average True Range 0.0449
ADX 14.88
+DI 18.6992
-DI 13.3748
Chandelier Exit (Long, 3 ATRs ) 0.4854
Chandelier Exit (Short, 3 ATRs ) 0.5947
Upper Bollinger Band 0.6046
Lower Bollinger Band 0.4868
Percent B (%b) 1.03
BandWidth 21.586953
MACD Line 0.0022
MACD Signal Line -0.0101
MACD Histogram 0.0123
Fundamentals Value
Market Cap 21.78 Million
Num Shares 35.8 Million
EPS -0.43
Price-to-Earnings (P/E) Ratio -1.42
Price-to-Sales 26.16
Price-to-Book 2.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.65
Resistance 3 (R3) 0.65 0.63 0.65
Resistance 2 (R2) 0.63 0.62 0.63 0.64
Resistance 1 (R1) 0.62 0.61 0.62 0.62 0.64
Pivot Point 0.60 0.60 0.60 0.60 0.60
Support 1 (S1) 0.59 0.59 0.59 0.59 0.58
Support 2 (S2) 0.57 0.58 0.57 0.57
Support 3 (S3) 0.56 0.57 0.57
Support 4 (S4) 0.56